Jiangsu Zhengrui Pharmaceutical Technology

Jiangsu Zhengrui Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in the China Medical City hub of Taizhou. The company specializes in the discovery and development of innovative small molecule therapeutics, with a primary focus on oncology, metabolic disorders, and autoimmune diseases. Its lead candidate, ZR-008, is a highly potent URAT1 inhibitor currently undergoing Phase 2 clinical trials for the treatment of hyperuricemia and gout. Beyond metabolic health, Zhengrui maintains a competitive oncology pipeline featuring targeted inhibitors for KRAS G12C, FGFR, and SHP2. The company leverages its internal R&D platform to advance high-potential drug candidates from early discovery through clinical proof-of-concept.